Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company centered on metabolic dysfunction-associated steatohepatitis (MASH), with its lead therapy Rezdiffra (resmetirom) and a growing pipeline of liver-directed treatments. The MDGL news feed on Stock Titan aggregates company announcements and third-party coverage so readers can follow how Madrigal’s clinical, regulatory, and commercial activities evolve over time.
News about Madrigal frequently highlights new clinical data from its Phase 3 MAESTRO program, including imaging, biomarker, and quality-of-life results in patients with MASH and compensated MASH cirrhosis (F4c). The company also issues updates on outcomes from major scientific meetings such as the American Association for the Study of Liver Diseases (AASLD) Liver Meeting and presentations at healthcare investment conferences.
Investors and healthcare observers will see regular press releases on Rezdiffra’s commercial performance, including product revenue, patient and prescriber adoption, and geographic expansion following regulatory approvals in the U.S. and Europe. Madrigal also reports on licensing transactions that expand its MASH pipeline, such as global agreements for an oral GLP-1 receptor agonist and ervogastat, a DGAT-2 inhibitor intended for combination use with Rezdiffra.
Additional news items cover corporate and capital structure developments disclosed via Form 8-K filings, including financing agreements, credit facilities, and governance matters such as annual meeting results and equity inducement awards under stock plans. For users tracking MDGL stock, this page offers a centralized view of Madrigal’s latest disclosures related to Rezdiffra, its broader MASH program, and key financial and strategic milestones. Bookmark this feed to monitor new data releases, regulatory and commercial updates, and pipeline progress that may influence the company’s long-term outlook.
Madrigal Pharmaceuticals announced its support for the fifth International NASH Day on June 9, 2022, highlighting its ongoing commitment to enhancing education and care for patients with non-alcoholic steatohepatitis (NASH). The campaign, led by the Global Liver Institute, aims to raise awareness about the liver disease. Madrigal's initiatives include partnerships with community organizations, unrestricted grants to various liver health programs, and the launch of the NASH Explored campaign for healthcare providers, aimed at disseminating vital information regarding NASH.
Madrigal Pharmaceuticals (NASDAQ: MDGL) has announced its participation in three upcoming investor conferences focused on healthcare. The events include the Jefferies Global Healthcare Conference on June 9, 2022, the Goldman Sachs Annual Global Healthcare Conference on June 14, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022. Presentations will be available via webcast and can be re-watched on the company's website. Madrigal is developing treatments for non-alcoholic steatohepatitis (NASH), with its leading candidate, resmetirom, currently in Phase 3 trials.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in two investor conferences on May 24, 2022. The company will host a fireside chat at the H.C. Wainwright Global Life Sciences Conference at 7:00 AM ET, followed by another at the UBS Global Healthcare Conference at 8:30 AM ET. Both presentations will be available via webcast and archived for later replay on the Madrigal website. The company focuses on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), with its lead candidate resmetirom under evaluation in Phase 3 studies.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced that four abstracts, including a late-breaker on the MAESTRO-NAFLD-1 study, were accepted for oral presentation at the EASL International Liver Congress. The Phase 3 study reinforced resmetirom's safety and efficacy for treating non-cirrhotic NASH. The company anticipates disclosing topline data from the MAESTRO-NASH by Q4 and plans to file for accelerated approval next year. Additionally, Madrigal secured a $250 million term loan facility to support its clinical development and potential U.S. launch of resmetirom.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will announce its Q1 2022 financial results on May 9, 2022, at 6:30 am ET. The announcement will include updates on their clinical programs and further results from the Phase 3 MAESTRO-NAFLD-1 study. Following the press release, a conference call is scheduled for the same day at 8:00 am ET. Investors can access the live webcast on Madrigal's website, where an archived version will be available post-event. Madrigal focuses on novel therapies for non-alcoholic steatohepatitis (NASH), with its lead candidate, resmetirom, in Phase 3 trials.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 8:00 AM ET. The management team will engage in a fireside chat, which will be webcast live. An archived recording will be available post-event on their website. Madrigal focuses on innovative therapeutics for non-alcoholic steatohepatitis (NASH) and leads with resmetirom, currently in Phase 3 studies.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported significant advancements in its clinical development for non-alcoholic steatohepatitis (NASH) in a recent press release. Key highlights include achieving primary endpoints in the MAESTRO-NAFLD-1 safety study, indicating that resmetirom is safe and effective in reducing liver fat and atherogenic lipids. Financially, the company reported cash reserves of $270.3 million, down from $284.1 million year-over-year, with operating expenses increasing to $242.5 million. The leadership team has been bolstered with new roles to enhance operational capacity.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced positive topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom, a treatment for non-alcoholic steatohepatitis (NASH). The 52-week double-blind study with 969 patients demonstrated safety and tolerability at doses of 80 mg and 100 mg. Significant reductions in liver fat and atherogenic lipids were achieved, with nearly half of the 100 mg group experiencing a 50% reduction in liver fat. The company plans to share more data from this trial, reinforcing its regulatory strategy for NASH treatment.
Madrigal Pharmaceuticals (NASDAQ: MDGL) plans to announce the topline results from its Phase 3 MAESTRO-NAFLD-1 study of resmetirom on January 31, 2022, at 7:00 am EST. The subsequent conference call is scheduled for 8:00 am EST the same day. This study aims to provide insights into resmetirom's effectiveness for treating fatty liver diseases, particularly non-alcoholic steatohepatitis (NASH). Resmetirom is a first-in-class, liver-directed, thyroid hormone receptor (THR)-β selective agonist currently evaluated in two Phase 3 trials.
Madrigal Pharmaceuticals (NASDAQ: MDGL) appointed Dr. Dominic F. Labriola as Senior Vice President and Chief Data and Analytics Officer. With 35 years of experience, Dr. Labriola previously led global biometrics at Bristol Myers Squibb and will aid in advancing Madrigal's Phase 3 clinical trials for resmetirom, a treatment for non-alcoholic steatohepatitis (NASH). The company anticipates significant data readouts in 2022 that could transform NASH patient care. This strategic hire supports Madrigal's mission to address unmet medical needs in fatty liver diseases.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
